Auro Laboratories Ltd vs Cohance Lifesciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Auro Laboratories Ltd is ₹ 239.1 as of 30 Apr 15:30 . The P/E Ratio of Auro Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 years The Market Cap of Auro Laboratories Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 years The revenue of Auro Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Cohance Lifesciences Ltd for the Dec '25 is ₹ 550.71 crore as compare to the Mar '25 revenue of ₹ 852.47 crore. This represent the decline of -35.4% The ebitda of Auro Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Cohance Lifesciences Ltd for the Dec '25 is ₹ 96.65 crore as compare to the Mar '25 ebitda of ₹ 225.49 crore. This represent the decline of -57.14% The net profit of Auro Laboratories Ltd changed from ₹ 0.75 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 29.02 crore over 7 quarters. This represents a CAGR of -42.04% The Dividend Payout of Auro Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Auro Laboratories Ltd

Auro Laboratories Limited, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API).
Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes.
The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra.
The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards.
Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company's primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments.

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

FAQs for the comparison of Auro Laboratories Ltd and Cohance Lifesciences Ltd

Which company has a larger market capitalization, Auro Laboratories Ltd or Cohance Lifesciences Ltd?

Market cap of Auro Laboratories Ltd is 149 Cr while Market cap of Cohance Lifesciences Ltd is 18,476 Cr

What are the key factors driving the stock performance of Auro Laboratories Ltd and Cohance Lifesciences Ltd?

The stock performance of Auro Laboratories Ltd and Cohance Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Auro Laboratories Ltd and Cohance Lifesciences Ltd?

As of May 4, 2026, the Auro Laboratories Ltd stock price is INR ₹239.1. On the other hand, Cohance Lifesciences Ltd stock price is INR ₹482.95.

How do dividend payouts of Auro Laboratories Ltd and Cohance Lifesciences Ltd compare?

To compare the dividend payouts of Auro Laboratories Ltd and Cohance Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.